Genomic Alterations and Targeted Therapy in Gastric and Esophageal Adenocarcinoma

详细信息    查看全文

• 作者：Eirini Pectasides ; MD ; PhD ; ^{eirini_pectasides@dfci.harvard.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Gastric adenocarcinoma ; esophageal adenocarcinoma ; genomics ; targeted therapy
• 刊名：Clinical Therapeutics
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：38
• 期：7
• 页码：1589-1599
• 全文大小：298 K

文摘

Gastric and esophageal adenocarcinomas are common and aggressive malignancies. Systemic therapy for these tumors is based primarily on cytotoxic chemotherapy, but outcomes remain poor. Precision medicine, where treatments are tailored to specific molecular abnormalities of tumors, holds great promise for improving outcomes in this disease.

Methods

A search was performed in PubMed to identify studies that have characterized the molecular basis of gastric and esophageal adenocarcinoma, as well as clinical trials exploring targeted therapies in this disease.

Findings

Recent genomic studies have identified potentially targetable genomic alterations in gastroesophageal adenocarcinoma. Specifically, The Cancer Genome Atlas study defined 4 subgroups of gastric cancer, each harboring distinct genomic features. However, development of targeted therapies for gastroesophageal cancer has been challenging. The only biomarker-driven therapy in clinical practice, trastuzumab for the ~15% of patients with human epidermal growth factor receptor 2−positive disease, is modestly effective, extending median overall survival by 2.7 months. Clinical trials of other targeted therapies, including epidermal growth factor receptor, fibroblast growth factor receptor 2, and MET inhibitors, have had disappointing results so far.

Implications

The availability of genomic tools provides an unprecedented opportunity to develop new rational therapeutic strategies. New trial designs of targeted therapies in biomarker-selected patient populations have the potential to improve outcomes in this lethal disease. As these clinical trials are being developed, it is increasingly important to incorporate correlative studies that will allow us to identify biomarkers of response or resistance to targeted therapies.